Clinical Study of 177Lu-JH040182 in Patients With FAP-Positive Malignancies

Phase 1 Active not recruiting 3 enrolled First Affiliated Hospital of Fujian Medical University

NaSingle-groupOpen-labelTreatment

Summary

This first-in-human study aimed to assess the safety and internal radiation dosimetry of 177Lu-JH040182, a novel FAP-targeted radiopharmaceutical, in patients with FAP-positive tumors. All patients underwent screening via 68Ga-FAPI PET/CT. Those confirmed to have FAP-positive lesions on PET imaging received administration of 177Lu-JH040182, and serial-time-point SPECT images were acquired for internal radiation dosimetry calculations.

Timeline

Start: 2025-04-01
Primary completion: 2026-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-JH040182	Unknown	5550 mbq	Intravenous
Subject	177Lu-JH040182	Unknown	7500 mbq	Intravenous

Indications

No indication recorded.